Top of the morning to you, and a fine one it is. A shiny sun and cool breezes are enveloping the Pharmalot campus, where the short person is sleeping in and the official mascot is searching for things to chew on. This means we are free to fire up the coffee kettle and brew another cup of stimulation. The neurons need all the help they can get, you know? Meanwhile, here are a few items of interest to help you get going. And by the way, we are hosting a chat today at 1 p.m. ET to discuss the state of the pharmaceutical industry, such as it is. So turn on and tune in. Meanwhile, have a great day …

The FDA plans to release guidance outlining its conditions for approving a Covid-19 vaccine, including a requirement that any vaccine be at least 50% more effective than a placebo in preventing the virus, The Wall Street Journal reports. No vaccine would be approved unless a company “clearly demonstrated” proof of safety and effectiveness through a clinical study, and would not be approved simply if it leads to antibodies in the bloodstream of patients, on grounds that it is not known what level of antibodies will confer protection to patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Huzzah, if true!? FDA is NOT looking for a secondary endpoint with a COVID-19 vaccine: “would not be approved simply if it leads to antibodies in the bloodstream of patients, on grounds that it is not known what level of antibodies will confer protection to patients.”

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy